This Article Full Text (PDF) All Versions of this Article: 0269881106065102v1 21/1/102    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hedges, D. W. Articles by Larcher, A. M. Search for Related Content PubMed PubMed Citation Articles by Hedges, D. W. Articles by Larcher, A. M. Pubmed/NCBI databases Medline Plus Health Information Anxiety Phobias Social Bookmarking                   What's this?

The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials

Department of Psychology, Brigham Young University, Provo, UT, USA, dawson_hedges{at}byu.edu

Bruce L. Brown

Department of Psychology, Brigham Young University, Provo, UT, USA

David A. Shwalb

Department of Psychology, Brigham Young University, Provo, UT, USA

Kirk Godfrey

Department of Psychology, Brigham Young University, Provo, UT, USA

A. Manja Larcher

Department of Psychology, Brigham Young University, Provo, UT, USA

Social anxiety disorder is associated with impairment in social and occupational functioning, significant personal distress and a possible economic burden, resulting in a reduction in quality of life. To understand better the efficacy of selective serotonin reuptake inhibitors in social anxiety disorder, randomized, double-blind, placebo-controlled trials were evaluated.

Pubmed and PsychINFO electronic databases were searched for social anxiety disorder, social phobia, selective serotonin reuptake inhibitors, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine and sertraline. Fifteen published, randomized, double-blind, placebo-controlled trials of selective serotonin reuptake inhibitors in social anxiety disorder were identified. Design, subject number, drug and dose, trial length, rating instruments, and baseline and end point data were extracted and then verified independently by a second investigator. Effect sizes were calculated from mean changes in drug and placebo groups in the Liebowitz Social Anxiety Scale and the Sheehan Disability Scale, as well as from other scales where available. For the binary data of the Clinical Global Impression of Change scores, log-odds ratios (the effect-size measure appropriate for binary data) were calculated from proportion changes.

Effect sizes for the Liebowitz Social Anxiety Scale ranged from -0.029 to 1.214. Effect sizes for the Sheehan Disability Scale ranged from 0.203 to 0.480 for work, 0.237 to 0.786 for social function, and 0.118 to 0.445 for family function. The log-odds ratios for Clinical Global Impression of Change scores ranged from 0.644 to 3.267. Consistent with previous studies, selective serotonin reuptake inhibitors appear more effective than placebo for social anxiety disorder, with improvement extending into social and occupational function.

Key Words: social anxiety disorder • selective serotonin reuptake inhibitors • meta-analysis

This version was published on January 1, 2007

Journal of Psychopharmacology, Vol. 21, No. 1, 102-111 (2007)
DOI: 10.1177/0269881106065102


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Gale and O. Davidson Tired and anxious BMJ, October 1, 2008; 337(oct01_2): a1241 - a1241. [Full Text]